...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Haematologica >Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma | Haematologica
【24h】

Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma | Haematologica

机译：CD45阴性的多发性骨髓瘤患者接受大剂量治疗的生存期短于CD45阳性的多发性骨髓瘤患者。血液学

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND OBJECTIVES: CD45 is a critical regulator of signaling threshold in immune cells. There are clinical and animal studies suggesting that the CD45-negative phenotype is the phenotype of progressive multiple myeloma (MM). The aims of this study were to confirm this hypothesis and to test the prognostic value of CD45 expression in newly diagnosed MM patients. DESIGN AND METHODS: In a retrospective study of 95 newly diagnosed MM patients treated with high dose therapy we used 4-color flow cytometry to determine CD45 expression and correlated the immunophenotipic data with clinical data. RESULTS: Thirty of 95 patients (31.5%) lacked CD45 expression at diagnosis. The CD45 phenotype significantly affected the overall survival (OS) of the patients, like the most common presenting prognostic parameters analyzed including b-2-microglobulin, age and 14q32 translocations. CD45 negative MM patients had a significantly worse OS than did CD45 positive cases of MM: 28.7% cumulative survival at 4 years, median 42 months vs not reached; p = 0.004. Furthermore, CD45 remained the only parameter adversely affecting OS in multivariate analysis. INTERPRETATION AND CONCLUSIONS: The CD45 negative phenotype could reflect the phenotype of progressive disease in relation to the intrinsic malignancy of the MM clone. Indeed, CD45 negative myeloma cells appear to have a greater capacity to circulate, disseminate and clone as well as being less sensitive to apoptosis.
机译：背景与目的：CD45是免疫细胞信号转导阈值的关键调节因子。有临床和动物研究表明CD45阴性表型是进行性多发性骨髓瘤（MM）的表型。这项研究的目的是证实这一假设并检验CD45表达在新诊断的MM患者中的预后价值。设计与方法：在一项对95例接受大剂量治疗的新诊断MM患者的回顾性研究中，我们使用了四色流式细胞术来确定CD45的表达并将免疫表型数据与临床数据相关联。结果：95例患者中有30例（31.5％）在诊断时缺乏CD45表达。 CD45表型显着影响患者的总体生存（OS），例如分析的最常见的预后参数，包括b-2-微球蛋白，年龄和14q32易位。 CD45阴性MM患者的OS显着低于CD45阳性MM：4年的累积生存率为28.7％，中位数为42个月，而未达到。 p ＝ 0.004。此外，在多变量分析中，CD45仍然是唯一对OS产生不利影响的参数。结论与结论：CD45阴性表型可以反映出与MM克隆的固有恶性有关的进行性疾病表型。实际上，CD45阴性骨髓瘤细胞似乎具有更高的循环，传播和克隆能力，并且对凋亡的敏感性较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号